PCa is a radiation-sensitive tumor and the development of small-molecule PSMA inhibitors has rendered PSMA ligand-coupled radionuclide diagnosis and treatment of PCa a research hotspot. This evidence concerns the gene FOLH1 and posterior cortical atrophy.